相关连接：
http://www.clovisoncology.com/pr ... iagnostics/co-1686/
http://www.inspire.com/groups/lu ... sion/co-1686-trial/
http://www.inspire.com/groups/lu ... -trials-or-results/
Abstract 1791: CO-1686, a novel mutant-selective EGFR inhibitor, overcomes T790M mediated resistance in Non-Small Cell Lung Cancer (NSCLC)
Annette O. Walter1, Robert Tjin2, Henry Haringsma1, Kevin Lin1, Alex Dubrovskiy2, Kwangho Lee2, Thia St. Martin2, Russell Karp2, Zhendong Zhu2, Deqiang Nu2, Mariana Nacht2, Kenichi Suda3, Tetsuya Mitsudomi3, Russell C. Petter2, William F. Westlin2, Juswinder Singh2, Mitch Raponi1, and Andrew Allen1
1Clovis Oncology, San Francisco, CA
2Avila Therapeutics, Bedford, MA
3Aichi Cancer Center Hospital, Nagoya, Japan
Introduction: Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. However, clinical efficacy is limited by the development of resistance. The most common mechanism of resistance is a second site mutation within exon 20 of EGFR (T790M), observed in ~50% of cases. CO-1686 is an irreversible kinase inhibitor that targets the mutant forms of EGFR by inhibiting the common activating mutations (L858R, delE746-A750) and the gatekeeper mutation (T790M) but not the wild-type receptor. Therefore, CO-1686 has the potential to effectively treat first- and second-line NSCLC patients with EGFR mutations without causing the dose limiting toxicities associated with approved EGFR kinase inhibitors or those in clinical development. Experimental procedures: Using structure-based drug design, CO-1686, a covalent, irreversible small molecule, which selectively inhibits mutant EGFR, was identified. CO-1686 potency was assessed against four common EGFR mutations (L858R, delE746-A750, L858R/T790M and delE746-A750/T790M) using in vitro biochemical and cell-based assays. Antitumor activity of CO-1686 as a single agent was assessed in NSCLC xenograft models harboring EGFR mutations: H1975 (L858R/T790M) and HCC827 (delE746-A750). Pharmacodynamic studies were performed to evaluate effects on cell survival and EGFR signaling. Results: In vitro and in vivo pharmacology studies focused on evaluating CO-1686 potency in four EGFR mutations common in NSCLC patients: L858R, delE746-A750, L858R/T790M and delE746-A750/T790M. CO-1686 was shown to be active against all four EGFR mutants. Effects of CO-1686 on cell proliferation and EGFR signaling were evaluated in HCC827 cells (delE746-A750) and its erlotinib-resistant clone, HCC827-EPR harboring the second site mutation T790M (delE746-A750/T790M). CO-1686 inhibited cell proliferation in both cell lines equally (GI50 values of 12 nM in the parental line and 19 nM in the T790M-positive clone). In mouse xenograft studies, oral dosing of CO-1686 in H1975 double mutant (L858R/T790M) and in HCC827 single mutant (delE746-A750) models caused tumor shrinkage as a single agent in a dose-dependent manner. Different dosing schedules were explored. Conclusions: Our results establish CO-1686 as a potent, mutant-selective EGFR inhibitor with excellent in vivo activity in mice bearing tumors with activating EGFR mutations as well as the resistance mutation T790M. These data suggest that treatment with CO-1686 as a single agent can overcome T790M-mediated drug resistance in NSCLC. Initially, clinical development will focus on NSCLC patients with mutant EGFR.
http://cancerres.aacrjournals.or ... bstracts/1791?rss=1 |
跨越十年丨憨叔靶向轮换的感悟及思路
我们在筷子治疗九周年纪念文章《跨越九年丨憨叔靶向轮换传承和发扬 --筷子奥希替尼
egfr19突变，16个月耐药，后续该如何
2023.7月爸爸确诊肺癌晚期，全身多处骨转 脑转，基因检测egfr19突变，单用阿美11个月
[9.20更新紧急求助］K药单免，肺部大
我父亲5月30,6月20，分别使用两次K药治疗。后因为肠道免疫副反应停止了K药直到现在.
免疫治疗的副作用有何征兆？可以预防
我们常说的抗肿瘤免疫治疗，多指以PD-1/PD-L1抑制剂为代表的免疫抑制剂，通过激活患
建议收藏！肺癌ALK患者靶向药耐药后
作者：闵
ALK突变常被众多病友称为“钻石突变”，不单是由于对应的靶向药价格高昂，更
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
千斤顶
显身卡
